Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden
2016 (English)In: Future Oncology, ISSN 1479-6694, E-ISSN 1744-8301, Vol. 12, no 8, 1025-1038 p.Article in journal (Refereed) PublishedText
Aim: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden.
Methods: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor.
Results: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+ 1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate-and high-risk groups from year 2.
Conclusion: HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL.
Place, publisher, year, edition, pages
2016. Vol. 12, no 8, 1025-1038 p.
bladder cancer, budget impact, cost-consequences model, detection, economic evaluation, fluorescence cystoscopy, fulguration, hexaminolevulinate, recurrence, Sweden
Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-294602DOI: 10.2217/fon-2015-0021ISI: 000372796900006PubMedID: 26975197OAI: oai:DiVA.org:uu-294602DiVA: diva2:931055